We at TIEFEENBACHER PHARMACEUTICALS aim to improve peoples´ lives around the world by making medicines better affordable, better available, and better than before! That´s why we are excited to share that we have successfully prepared the launch of the generic versions of Abiraterone and the value-added product Abiraterone/Prednisolone for a market entry in Europe.

For the mono product Abiraterone, we were able to achieve a day one launch after patent expiration, making this important therapy finally more affordable for patients around the world. With the combination product Abiraterone/Prednisolone, we offer a value-added product which comes in a special combi blister packaging improving patients´ compliance, enhancing physicians´ convenience, and protecting the environment.

Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners. A launch in further international markets will follow soon.

AET Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on:www.aet.eu 

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963 
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve people’s lives by creating pharmaceuticals more affordable, more available, and better than before.Further information about our better healthcare solutions and in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) can be found on www.tiefenbacher.com or you can contact us info@tiefenbacher.com